A vs AJG Stock Comparison

Scores Breakdown

Metric	A	AJG
📈 Growth	18/30	14/30
💰 Profitability	16/20	14/20
🏦 Financial Health	7/20	16/20
💵 Valuation	9/20	8/20
⚠️ Risk (lower is better)	7/10	5/10
Overall Score	53/100	57/100

Side-by-Side Summaries

A Analysis	AJG Analysis
📈 Growth & Financial Trajectory Over eight quarters, Revenues rose from about $1.66B to $1.84B, a positive trend, with a mid-2025 dip. Net income fluctuated from $308M–$434M, ending near $339M in 2026 Q2. The sequence shows top-line resilience but earnings volatility, implying improving mix or cost management but not a steady uplift in profitability. 💰 Margins & Cash Flow Gross Margin is generally in the mid-50s percentile, peaking around 63% in 2024 Q2 and typical ~50–55% in other quarters. Operating Margin has run in the high-teens to low-20s percent range on Revenues of ~$1.6–$1.8B. Operating cash flow remains positive across quarters (roughly $0.27–$0.55B), while investing cash flow is negative (capital outlays), and financing cash flow is often negative, reflecting debt/return actions. 🛡️ Balance Sheet & Liquidity Total Assets (~~$11–$13B) exceed Liabilities (~~$4.8–$6B) with Equity frequently negative, signaling balance-sheet rehabilitation needs. Current assets vs current liabilities suggests solid liquidity (working capital positive); long-term debt remains a meaningful load but generally manageable within cash flows. ⚠️ Key Drivers & Risks Drivers: Life sciences capex & instrument upgrades; continued demand for laboratory testing and automation. Risks: Earnings volatility from cyclic lab-spend; structural negative equity raises valuation sensitivity and balance-sheet risk.	📈 Growth & Financial Trajectory From 2024 Q2 to 2026 Q1 AJG exhibits a roller-coaster 8-quarter path. Revenue rose to a peak of $4.758B in 2026 Q1 but ended the window at $2.8068B in 2024 Q2, a decline of about 41% over the span. Net income followed a similar volatile pattern, moving from $823M in 2026 Q1 to $285.4M in 2024 Q2, with a notable trough in 2025 Q4 ($210.5M). The sequence includes a mid-window high around 2025 Q1 ($704.4M) before subsiding. Overall, the backdrop shows upside momentum into early 2026 after mid-2024 troughs, but the end-state remains materially below the peak start level. These dynamics imply improving but uneven near-term growth and earnings power. 💰 Margins & Cash Flow Profitability relief is uneven. Gross-margin proxy (revenues minus costs) fluctuates, with an early-2026 reading around 21.9% (4,758 vs 3,715) but a dip in 2025 Q4 near 5%, reflecting mix/cost pressure. A rising trend into 2025–2026 suggests improving operating leverage, albeit from a weak mid-2024 base. Operating cash flow remained positive in most quarters, notably $957M in 2026 Q1 and $753M in 2025 Q1, while total cash flow was pressured by investing/financing outflows in quarters like 2025 Q2. Cash flow patterns indicate solid core cash generation, offset by episodic outlays. 🛡️ Balance Sheet & Liquidity AJG carries a sizeable asset base with total assets around $78B (2026 Q1), current assets about $42B and current liabilities near $39.5B, yielding a modest current ratio (~1.06). Long‑term debt sits around $12–13B across recent quarters, with equity around $23–24B. The balance sheet shows solid liquidity and reasonable leverage (debt to equity well below 1), supporting resilience through cyclicality. ⚠️ Key Drivers & Risks Drivers: stable insurance brokerage demand and diversified risk-management services; potential uplift from data-driven analytics. Risks: revenue/earnings cyclicality, sensitivity to pricing and tax mix, and episodic volatility from large capital/dividend outlays could pressure near-term earnings and multiple.

A Analysis

AJG Analysis

📈 Growth & Financial Trajectory

Over eight quarters, Revenues rose from about $1.66B to $1.84B, a positive trend, with a mid-2025 dip. Net income fluctuated from $308M–$434M, ending near $339M in 2026 Q2. The sequence shows top-line resilience but earnings volatility, implying improving mix or cost management but not a steady uplift in profitability.

💰 Margins & Cash Flow

Gross Margin is generally in the mid-50s percentile, peaking around 63% in 2024 Q2 and typical ~50–55% in other quarters.
Operating Margin has run in the high-teens to low-20s percent range on Revenues of ~$1.6–$1.8B.
Operating cash flow remains positive across quarters (roughly $0.27–$0.55B), while investing cash flow is negative (capital outlays), and financing cash flow is often negative, reflecting debt/return actions.

🛡️ Balance Sheet & Liquidity

Total Assets (~~$11–$13B) exceed Liabilities (~~$4.8–$6B) with Equity frequently negative, signaling balance-sheet rehabilitation needs. Current assets vs current liabilities suggests solid liquidity (working capital positive); long-term debt remains a meaningful load but generally manageable within cash flows.

⚠️ Key Drivers & Risks

Drivers: Life sciences capex & instrument upgrades; continued demand for laboratory testing and automation.
Risks: Earnings volatility from cyclic lab-spend; structural negative equity raises valuation sensitivity and balance-sheet risk.

📈 Growth & Financial Trajectory

From 2024 Q2 to 2026 Q1 AJG exhibits a roller-coaster 8-quarter path. Revenue rose to a peak of $4.758B in 2026 Q1 but ended the window at $2.8068B in 2024 Q2, a decline of about 41% over the span. Net income followed a similar volatile pattern, moving from $823M in 2026 Q1 to $285.4M in 2024 Q2, with a notable trough in 2025 Q4 ($210.5M). The sequence includes a mid-window high around 2025 Q1 ($704.4M) before subsiding. Overall, the backdrop shows upside momentum into early 2026 after mid-2024 troughs, but the end-state remains materially below the peak start level. These dynamics imply improving but uneven near-term growth and earnings power.

💰 Margins & Cash Flow

Profitability relief is uneven. Gross-margin proxy (revenues minus costs) fluctuates, with an early-2026 reading around 21.9% (4,758 vs 3,715) but a dip in 2025 Q4 near 5%, reflecting mix/cost pressure. A rising trend into 2025–2026 suggests improving operating leverage, albeit from a weak mid-2024 base. Operating cash flow remained positive in most quarters, notably $957M in 2026 Q1 and $753M in 2025 Q1, while total cash flow was pressured by investing/financing outflows in quarters like 2025 Q2. Cash flow patterns indicate solid core cash generation, offset by episodic outlays.

🛡️ Balance Sheet & Liquidity

AJG carries a sizeable asset base with total assets around $78B (2026 Q1), current assets about $42B and current liabilities near $39.5B, yielding a modest current ratio (~1.06). Long‑term debt sits around $12–13B across recent quarters, with equity around $23–24B. The balance sheet shows solid liquidity and reasonable leverage (debt to equity well below 1), supporting resilience through cyclicality.

⚠️ Key Drivers & Risks

Drivers: stable insurance brokerage demand and diversified risk-management services; potential uplift from data-driven analytics.
Risks: revenue/earnings cyclicality, sensitivity to pricing and tax mix, and episodic volatility from large capital/dividend outlays could pressure near-term earnings and multiple.

Similar Companies

AMAT Score: 80 AME Score: 81 ANET Score: 84 GOOGL Score: 78 TMO Score: 75 WAT Score: 78

Top Rated Companies

View Top 20 →

MU "MICRON TECHNOLOGY INC"

AVGO "Broadcom Inc."

KMI "KINDER MORGAN, INC."

MNST "Monster Beverage Corp"

NEM "NEWMONT Corp /DE/"